Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca Ups Betting Ante On Moderna's Messenger RNA Technology

This article was originally published in Scrip

Executive Summary

Emboldened by results from their existing alliance on mRNA drugs for cardiovascular, metabolic and regenerative disease, AstraZeneca PLC and privately held Moderna Therapeutics LLC have decided to extend their focus to include candidates for the treatment of a range of cancers.


Related Content

Biopharma Unicorn Moderna Highlights Secretive Pipeline As Investors Await IPO
AstraZeneca’s Business Development Head Grady Outlines Strategy Mix
Deal Watch: AZ Ups mRNA Stake, Gilead's HIV Innovation, Hospira Returns Lucentis Biosimilar, Pfizer/Takeda End Distribution Deal
Moderna Signs Single Drug Deal With CF Expert Vertex For Up To $315m
Merck Bets Moderna's Cancer Vaccines Can Prime Patients For Immunotherapy





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts